A Noteworthy Case of Myasthenic Crisis Induced by Levofloxacin
DOI:
https://doi.org/10.17140/imoj-8-124Keywords:
Myasthenia gravis, Levofloxacin, Fluoroquinolones, Neuromuscular junction, Myasthenic crisis, Myasthenia Gravis Founda tion of America (MGFA) clinical classification, Antibiotic-induced exacerbation, Ocular muscle weakness, Respiratory muscle involvement, Treatment strategies, Molecular mechanisms, Adverse drug reactions, The coding symbols for a thesaurus of adverse reaction terms ( COSTART) frequency classificationAbstract
This case report discusses a patient with a past medical history of Myasthenia gravis who was admitted to the hospital for community-acquired pneumonia and was then sent into a myasthenic crisis secondary to treatment with Levofloxacin. Although Levofloxacin can be effective at resolving community-acquired pneumonia, this antibiotic can precipitate muscular pathologies in certain population subsets. This is an interesting case of an acute myasthenic crisis being induced by Levofloxacin, leading the patient into acute hypoxic respiratory failure. It is critical to thoroughly consider, and if possible, avoid, any class of medications that may affect muscular function in individuals with myasthenia gravis.
References
Podder V, Sadiq NM. Levofloxacin. Treasure Island (FL), USA: StatPearls Publishing; 2023. Website. https://www.ncbi.nlm.nih. gov/books/NBK545180/. Updated September 23, 2022. Ac-cessed February 1, 2024.
Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011; 1(1): 16-22. doi: 10.1177/1941875210382918
Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-asso-ciated myasthenia gravis exacerbation: Evaluation of postmar-keting reports from the US FDA adverse event reporting sys-tem and a literature review. Drug Saf. 2011; 34(10): 839-847. doi: 10.2165/11593110-000000000-00000
Sieb JP. Fluoroquinolone antibiotics block neuromuscular trans-mission. Neurology. 1998; 50(3): 804-807. doi: 10.1212/wnl.50.3.804
Krenn M, Grisold A, Wohlfarth P, et al. Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and in-duced by medical treatments. Front Mol Neurosci. 2020; 13: 156. doi: 10.3389/fnmol.2020.00156 Submit your article to this journal |https://openventio.org/online-manuscript-submission-system/ 7 Young A, et al
Koneczny I, Herbst R. Myasthenia gravis: Pathogenic effects of autoantibodies on neuromuscular architecture. Cells. 2019; 8(7): 671. doi: 10.3390/cells8070671
Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023; 68(1): 8-19. doi: 10.1002/mus.27832
Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med. 1997; 25(7): 1228- 1235. doi: 10.1097/00003246-199707000-00027
Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Fac-tors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019; 60(6): 693-699. doi: 10.1002/mus.26689
Bedlack RS, Sanders DB. On the concept of myasthenic crisis. J Clin Neuromuscul Dis. 2002; 4(1): 40-42. doi: 10.1097/00131402- 200209000-00009
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Internal Medicine (IMOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
